방사선종양학

본문글자크기
  • [​Radiother Oncol. ] Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial

    2016년 10월호
    [​Radiother Oncol. ] Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial

    NCC / 김진희, 김주영*

  • 출처
    ​Radiother Oncol.
  • 등재일
    2016 Sep
  • 저널이슈번호
    120(3):383-389. doi: 10.1016/j.radonc.2016.04.009. Epub 2016 Apr 18.
  • 내용

    바로가기  >



    Abstract

    BACKGROUND AND PURPOSE:

    The efficacy of prophylactic extended-field irradiation (EFI) plus concomitant cisplatin in patients with locally advanced uterine cervical cancer (LAUCC) is unknown, nor is it known whether tumor carbonic anhydrase IX (CA9) expression level, a hypoxia marker, influences survival outcome.

     

    MATERIAL AND METHODS:

    We recruited patients with UCC, FIGO stage IB1 with pelvic lymph node (LN) metastases to IVA with negative para-aortic LN on PET/CT. CA9 expression was examined and patients were randomized to either EFI or pelvic only radiotherapy (PRT) in each CA9 group. The primary outcomes were para-aortic recurrence-free survival (PARFS) and disease-free survival (DFS).

     

    RESULTS:

    Between 2006 and 2011, 79 patients with CA9-positive and 37 with CA9-negative tumors were enrolled, respectively. The median follow-up period was 69.2months (range 6.8-102.1). For CA9-positive patients, 5-year PARFS was 100% and 81.7% for those receiving EFI and PRT (p=0.007), respectively. DFS was 78.6% for EFI and 71.3% for PRT patients (p=0.353). For CA9-negative patients, 5y PARFS was 100% and 94.1% for EFI and PRT (p=0.317), respectively. DFS was 100% for EFI and 70.7% for PRT (p=0.018).

     

    CONCLUSION:

    EFI significantly reduced recurrences in PAN in patients with CA9-positive tumors, but survival outcome was not improved, due to high local recurrence and high distant metastases rates. This study indicates the necessity for new therapeutic strategies for LAUCC patients whose tumors show high CA9 expression.​ 

     

    Author information

    Kim JH1, Kim JY2, Yoon MS3, Kim YS4, Lee JH5, Kim HJ6, Kim H7, Kim YJ8, Yoo CW8, Nam BH9, Kim TH8, Kim SK8, Kim SH8, Kang S8, Seo SS8, Lim MC8, Park SY8.

    1Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.

    2Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. Electronic address: jooyoungcasa@ncc.re.kr.

    3Department of Radiation Oncology, Chonnam National University, Hwasun Hospital, Republic of Korea.

    4Department of Radiation Oncology, Asan Medical Center, Unviersity of Ulsan, College of Medicine, Seoul, Republic of Korea.

    5Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Republic of Korea.

    6Department of Radiation Oncology, Seoul National University, College of Medicine, Republic of Korea.

    7Department of Radiation Oncology, Inha University Hospital, Inha University, School of Medicine, Incheon, Republic of Korea.

    8Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.

    9Cancer Control and Policy Department, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. 

  • 키워드
    Carbonic anhydrase IX (CA9); Extended-field irradiation (EFI); Radiotherapy; Uterine cervical cancer
  • 연구소개
    본 연구는 국소진행된 자궁경부암 환자를 대상으로 종양저산소표지자 발현에 따른 대동맥림프절의 예방적 방사선치료의 효과를 보기 위하여 시행한 전향적 다기관연구의 조기결과데 대한 리포트임. 종양저산소증 표지자인 CA9 의 발현이 높은 자궁경부종양을 가진 환자에서 예방적 대동맥림프절 방사선치료를 함으로써 CA9 음성종양을 가진 환자에 비해 통계학적으로 유의하게 해당부위에서의 재발을 낮추어 줌을 알 수 있었음. 하지만 이것이 두 그룹간의 무병생존율이나 전체생존율의 이득으로 이어지지는 못하였음이 이 논문의 주요 결과임. 이번 분석은 초기에 등재되어 중앙 추적기간이 6년정도가 되는 114명의 환자를 대상으로 분석한 결과이고 이 임상시험에 등록된 전체 312명의 최종결과는 앞으로 흥미롭게 기다려지고 있음.
  • 덧글달기
    덧글달기
       IP : 18.227.209.251

    등록